Patient Assistance Program
Careers
Contact

Pipeline
Leadership
- Management Team
- Board of Directors
Medical Affairs
News & Investors
Careers
Contact

Pipeline
Leadership
Medical Affairs
News & Investors
Careers
Contact

Management Team
Board of Directors

MEDINFO
Adverse Event
Product Quality Complaint
Research Focus
Clinical Trials
CME Grant
Investigator Initiated Study
Find your field medical director

Atopic Dermatitis
Psoriasis

May 2022

May 2022

May 24, 2022

FDA Approves Dermavant’s VTAMA^® (tap ...

Read More

For Healthcare Professionals With Medical Questions

Find Your Field Medical Director

Recent Posts

Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA^® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA^® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
Dermavant to Present Data from Multiple Studies of VTAMA^® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting
Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA^® (tapinarof) cream, 1% for the treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old
Dermavant to Present Data from Multiple Studies of VTAMA^® (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference

Archives

Categories

Dermavant Sciences
News
RVT-201
RVT-501
RVT-502
RVT-504
Tapinarof

Find Us

Dermavant Sciences, Inc.
3780 Kilroy Airport Way
Suite 250
Long Beach, CA 90806
United States

Company
Medical Information
Compliance Program

Leadership
Careers
Contact
News & Investors

Pipeline
MEDINFO
Clinical Trials
Research Focus
CME Grant

Management Team
Board of Directors

Atopic Dermatitis
Psoriasis

Company
- Leadership
  - Management Team
  - Board of Directors
- Careers
- Contact
- News & Investors
Medical Information
- Pipeline
- MEDINFO
- Clinical Trials
- Research Focus
  - Atopic Dermatitis
  - Psoriasis
- CME Grant
Compliance Program

Copyright © 2023 Dermavant Sciences, Inc. All Rights Reserved. All trademarks are the property of Dermavant Sciences, GmbH.
Privacy Policy | Terms of Use | Terms of Sale – Independent Pharmacies | Terms of Sale – Wholesalers | US Wholesalers